SAN DIEGO—(BUSINESS WIRE)—Nov. 26, 2012—ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD), a biopharmaceutical companyfocused on innovative treatments that address unmet medical needs inneurological and related central nervous system disorders, todayannounced that it will host a conference call and webcast at 8:00 a.m.Eastern Time on Tuesday, November 27, 2012 to present the top-lineresults from its pivotal Phase III trial with pimavanserin in patientswith Parkinson’s disease psychosis (PDP).
The conference call may be accessed by dialing 866-783-2140 forparticipants in the U.S. or Canada and 857-350-1599 for internationalcallers (reference passcode 26249437). A telephone replay of theconference call may be accessed through December 11, 2012 by dialing888-286-8010 for callers in the U.S. or Canada and 617-801-6888 forinternational callers (reference passcode 47904115). The conference callalso will be webcast live on ACADIA’s website, www.acadia-pharm.com,under the investors section and will be archived there until December11, 2012.
About Pimavanserin
Pimavanserin is ACADIA’s proprietary small molecule that actsselectively as an antagonist/inverse agonist on serotonin 5-HT2Areceptors and is in Phase III development as a potential first-in-classtreatment for Parkinson’s disease psychosis. Pimavanserin can be takenorally as a tablet once-a-day. ACADIA discovered and holds worldwiderights to pimavanserin.
About Parkinson’s Disease Psychosis
According to the National Parkinson’s Foundation, about one millionpeople in the United States and from four to six million peopleworldwide suffer from Parkinson’s disease. Parkinson’s diseasepsychosis, or PDP, is a debilitating disorder that develops in up to 60percent of patients with Parkinson’s disease. Currently, there is noFDA-approved therapy to treat PDP in the United States. PDP, commonlyconsisting of visual hallucinations and delusions, substantiallycontributes to the burden of Parkinson’s disease and deeply affects thequality of life of patients. PDP is associated with increased caregiverstress and burden, nursing home placement, and increased morbidity andmortality. There is a large unmet medical need for new therapies thatwill effectively treat PDP without compromising motor control inpatients with Parkinson’s disease.
About ACADIA Pharmaceuticals
ACADIA is a biopharmaceutical company focused on innovative treatmentsthat address unmet medical needs in neurological and related centralnervous system disorders. ACADIA has a pipeline of product candidatesled by pimavanserin, which is in Phase III development as a potentialfirst-in-class treatment for Parkinson's disease psychosis. ACADIA alsohas clinical-stage programs for chronic pain and glaucoma incollaboration with Allergan, Inc. and two preclinical programs directedat Parkinson’s disease and other neurological disorders. All of ACADIA’sproduct candidates are small molecules that emanate from discoveriesmade using its proprietary drug discovery platform. ACADIA maintains awebsite at www.acadia-pharm.comto which ACADIA regularly posts copies of its press releases as well asadditional information and through which interested parties cansubscribe to receive email alerts.
Forward-Looking Statements
Statements in this press release that are not strictly historical innature are forward-looking statements. These statements include but arenot limited to statements related to the progress and timing of ACADIA’sdrug discovery and development programs, either alone or with a partner,including clinical trials and the results of clinical trials, and thebenefits to be derived from ACADIA’s product candidates, in each caseincluding pimavanserin. These statements are only predictions based oncurrent information and expectations and involve a number of risks anduncertainties. Actual events or results may differ materially from thoseprojected in any of such statements due to various factors, includingthe risks and uncertainties inherent in drug discovery, development andcommercialization, and collaborations with others, and the fact thatpast results of clinical trials may not be indicative of future trialresults. For a discussion of these and other factors, please refer toACADIA’s annual report on Form 10-K for the year ended December 31, 2011as well as ACADIA’s subsequent filings with the Securities and ExchangeCommission. You are cautioned not to place undue reliance on theseforward-looking statements, which speak only as of the date hereof. Thiscaution is made under the safe harbor provisions of the PrivateSecurities Litigation Reform Act of 1995. All forward-looking statementsare qualified in their entirety by this cautionary statement and ACADIAundertakes no obligation to revise or update this press release toreflect events or circumstances after the date hereof, except asrequired by law.
Source: ACADIA Pharmaceuticals Inc.
ACADIA Pharmaceuticals Inc.
Thomas H. Aasen, ExecutiveVice President,
Chief Financial Officer and Chief BusinessOfficer
(858) 558-2871